<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="83016">
  <stage>Registered</stage>
  <submitdate>28/07/2008</submitdate>
  <approvaldate>22/10/2008</approvaldate>
  <actrnumber>ACTRN12608000536369</actrnumber>
  <trial_identification>
    <studytitle>Kava Anxiety Depression Spectrum Study: A Human Clinical Trial to Treat Generalised Anxiety.</studytitle>
    <scientifictitle>Kava Anxiety Depression Spectrum Study: A Human Clinical Trial to Treat Generalised Anxiety.</scientifictitle>
    <utrn />
    <trialacronym>KADSS</trialacronym>
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Depression</healthcondition>
    <healthcondition>Anxiety</healthcondition>
    <conditioncode>
      <conditioncode1>Mental Health</conditioncode1>
      <conditioncode2>Anxiety</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Mental Health</conditioncode1>
      <conditioncode2>Depression</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>The intervention is an aqueous extract  from the peeled root of Kava (Piper methysticum). 5X 2.66g tablets (= 250mg of kavalactones per day) per day of either placebo or kava over 3-weeks.
1 week placebo washout period, followed by 2 x 1 weeks of either kava or placebo. (crossover).</interventions>
    <comparator>Placebo tablets (identical coating and size). Excipients- inert fillers e.g. starch</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>The Hamilton Anxiety Scale</outcome>
      <timepoint>Baseline, Weeks 1,2,3</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Montgomery-Asberg Depression Rating Scale (MADRS)</outcome>
      <timepoint>Weeks 0(baseline),1,2,3. True baseline measurement will start from week 1 (after randomisation)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Beck Anxiety Scale (BAI)</outcome>
      <timepoint>Week 1 (randomisation after placebo washout), Week 2, Week 3</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Chronic anxiety &gt;2 weeks (&gt;10 Beck Anxiety Inventory: BAI).</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>65</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Use of synthetic antidepressants.
Psychotic/ Bipolar illness. 
Significant suicidal ideation in the previous 6 months.
Diagnosed hepato-bilary disease/inflammation.
Substance abuse disorder including alcohol in the previous 6 months.
Use of benzodiazepines or opiates in the previous month.
Previous adverse reaction to kava. 
Seeing a psychologist or counsellor currently or in the previous month.
Lack of facility in written or spoken English.
Currently pregnant or lactating</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Participants are recuited via the mass media. After a 1 week placebo run-in, non-responders to placebo (excluded if they had &gt;50% reduction on the Hamilton Anxiety Scale (HAMA) or Beck Anxiety Inventory (BAI) are randomly allocated to an active or placebo group, which is crossed-over after one week. Randomisation was instigated by a non-affliated researcher, using randomised permutation. Allocation to Group A or Group B was concelled in an opaque envelope and was opened by a blinded researcher at the time of the participants randomisation.</concealment>
    <sequence>Randomisation was acheived via comuter-generated permuted block randomisation. Randomisation was stratified for sex, and high and low depression on the Beck Depression Inventory II (BDI II) (above or below 10 on the BDI II i.e. Hi or Low BDI II female; Hi or Low BDI II Male.</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2 / Phase 3</phase>
    <anticipatedstartdate>1/07/2008</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>60</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>University of Queensland</primarysponsorname>
    <primarysponsoraddress>The University of Queensland, Sir Fred Schonell Drive, St Lucia, Brisbane, Queensland, Australia, 4076.</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>University of Queensland</fundingname>
      <fundingaddress>Floor K, Mental Health Centre, Royal Brisbane and Women's Hospital (RBWH). Queensland.
 
Herston rd, Herston 4006, Queensland</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>KADSS is a 3-week human clinical trial using a water soluble extract of kava to treat anxiety. We aim to determine whether this extract is safe and effective in reducing anxiety. We also are exploring the effects of kava on depression levels.</summary>
    <trialwebsite>NIL</trialwebsite>
    <publication>NIL</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>The University of Queensland Medical Ethics committee</ethicname>
      <ethicaddress>The University of Queensland, Sir Fred Schonell Drive, St Lucia, Brisbane, Queensland, Australia, 4076.</ethicaddress>
      <ethicapprovaldate>31/03/2008</ethicapprovaldate>
      <hrec>2008000340</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Jerome Sarris</name>
      <address>Floor K, Mental Health Centre, Royal Brisbane and Women's Hospital (RBWH), Herston rd, Herston, 4006, Queensland</address>
      <phone>07 3878 8989</phone>
      <fax />
      <email>j.sarris@uq.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Jerome Sarris</name>
      <address>Floor K, Mental Health Centre, Royal Brisbane and Women's Hospital (RBWH). Herston rd, Herston. 4006, Queensland.</address>
      <phone>07 3878 8989</phone>
      <fax />
      <email>j.sarris.uq.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Jerome Sarris</name>
      <address>Floor K, Mental Health Centre, Royal Brisbane and Women's Hospital (RBWH). Herston rd, Herston 4006, Queensland</address>
      <phone>07 3878 8989</phone>
      <fax />
      <email>J.Sarris@uq.edu.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>